The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Regulatory News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Diurnal Group plc

21 Sep 2022 10:20

RNS Number : 1496A
Panmure Gordon (UK) Limited
21 September 2022
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Gordon (UK) Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Diurnal Group PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Diurnal Group PLC

(d) Date dealing undertaken:

20 Sep 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

10p Ordinary

Purchase

 

95,028

0.2678

 

0.2678

 

10p Ordinary

Sales

0

0

 

0

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

21/09/2022

Contact name:

Mohammed Jamal

Telephone number:

020 7886 2780

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERMZGZLLMLGZZG
Date   Source Headline
12th May 20213:44 pmRNSDirector Dealings
12th May 20211:58 pmRNSHolding(s) in Company
12th May 202112:08 pmRNSHolding(s) in Company
12th May 20217:00 amRNSAgreement with Citrine Medicine for Efmody
11th May 20214:43 pmRNSHolding(s) in Company
11th May 20213:25 pmRNSHolding(s) in Company
10th May 202110:26 amRNSResult of General Meeting
23rd Apr 20217:00 amRNSGrant of second European Patent for Alkindi
21st Apr 202111:51 amRNSResult of Placing and Subscription
21st Apr 20217:00 amRNSProposed Placing, Subscription and Open Offer
15th Apr 20219:49 amRNSRequest for Efmody Orphan Designation withdrawn
26th Mar 20212:06 pmRNSSecond Price Monitoring Extn
26th Mar 20212:00 pmRNSPrice Monitoring Extension
26th Mar 202111:57 amRNSEMA issues positive opinion for second product
15th Mar 20217:00 amEQSEdison Investment Research Limited: Diurnal Group (DNL): Initiation - Improving treatments for endocrine disorders
10th Mar 20219:44 amRNSHolding(s) in Company
8th Mar 20215:34 pmRNSHolding(s) in Company
25th Feb 20217:15 amEQSHardman & Co Research: Diurnal Group (DNL): Attention turning to Chronocort(R)
24th Feb 20217:00 amRNSShares and AJ Bell Investor Evening Webinar
23rd Feb 20217:01 amRNSInterim Results
23rd Feb 20217:00 amRNSChronocort agreement with Consilient for Nordics
2nd Feb 20217:01 amRNSChronocort results published in JCEM
27th Jan 20219:00 amRNSPrice Monitoring Extension
27th Jan 20217:00 amRNSChina licencing agreement with Citrine for Alkindi
14th Jan 20217:01 amRNSBusiness and trading update
14th Jan 20217:00 amRNSAgreement with Eton for Alkindi extended to Canada
13th Jan 202110:07 amRNSAgreement with Er-Kim for distribution in Turkey
12th Jan 20217:00 amRNSChronocort MAA Submitted to the UK MHRA
11th Jan 20217:00 amRNSGrant of European Patent for Chronocort
22nd Dec 20203:29 pmRNSIssue of LTIP Awards
11th Dec 20202:02 pmRNSExercise of Options, Issue of Equity and TVR
23rd Nov 20207:00 amRNSExercise of Options, Issue of Equity and TVR
20th Nov 202012:06 pmRNSResult of Annual General Meeting
20th Nov 20207:00 amRNSGrant of European Patent for Alkindi
10th Nov 20207:00 amRNSNotice of Interim Results
2nd Nov 20204:47 pmRNSHolding(s) in Company
30th Oct 202011:34 amRNSHolding(s) in Company
30th Oct 20208:37 amRNSHolding(s) in Company
29th Oct 202010:30 amRNSHolding(s) in Company
29th Oct 20209:25 amRNSDirector Dealings
28th Oct 202012:49 pmRNSResult of General Meeting and Open Offer
21st Oct 20207:00 amRNSMAA for Alkindi submitted to Swissmedic
19th Oct 20207:00 amRNSVesting of LTIP awards
9th Oct 202010:37 amRNSResult of Placing, Open Offer and Notice of GM
9th Oct 20207:00 amRNSProposed Placing and Open Offer
8th Oct 20202:28 pmRNSPosting of Annual Report and AGM Notice
30th Sep 20204:41 pmRNSSecond Price Monitoring Extn
30th Sep 20204:35 pmRNSPrice Monitoring Extension
30th Sep 20208:15 amEQSHardman & Co Research: Diurnal (DNL): And then there were three
30th Sep 20207:00 amRNSAlkindi Sprinkle approved by US FDA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.